Exelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Vanguard Group Inc.

Vanguard Group Inc. raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,429,252 shares of the biotechnology company's stock after purchasing an additional 121,750 shares during the quarter. Vanguard Group Inc. owned 10.31% of Exelixis worth $979,994,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of EXEL. Tri Ri Asset Management Corp purchased a new position in Exelixis in the third quarter valued at approximately $4,396,000. Blue Trust Inc. raised its stake in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 8,208 shares during the period. Range Financial Group LLC purchased a new position in shares of Exelixis in the 4th quarter valued at $994,000. FMR LLC lifted its holdings in shares of Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock valued at $63,891,000 after acquiring an additional 140,568 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after purchasing an additional 704,786 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of NASDAQ:EXEL traded up $0.54 during trading on Wednesday, reaching $36.93. 327,703 shares of the company's stock traded hands, compared to its average volume of 2,139,043. The stock has a market capitalization of $10.34 billion, a P/E ratio of 20.77, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.02. The company has a 50 day moving average of $35.72 and a 200-day moving average of $33.46.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the company's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the transaction, the director now owns 33,514 shares of the company's stock, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on EXEL. Oppenheimer lowered Exelixis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. JMP Securities reissued a "market outperform" rating and set a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. Wells Fargo & Company lowered shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price target for the company. in a report on Monday, February 24th. BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Guggenheim reissued a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.